Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial
Journal
The Lancet. Oncology
Journal Volume
23
Journal Issue
8
Pages
995
Date Issued
2022-08
Author(s)
Kelley, Robin Kate
Rimassa, Lorenza
Kaseb, Ahmed
Qin, Shukui
Zhu, Andrew X
Chan, Stephen L
Melkadze, Tamar
Sukeepaisarnjaroen, Wattana
Breder, Valery
Verset, Gontran
Gane, Edward
Borbath, Ivan
Rangel, Jose David Gomez
Ryoo, Baek-Yeol
Makharadze, Tamta
Merle, Philippe
Benzaghou, Fawzi
Banerjee, Kamalika
Hazra, Saswati
Fawcett, Jonathan
Yau, Thomas
Abstract
Cabozantinib has shown clinical activity in combination with checkpoint inhibitors in solid tumours. The COSMIC-312 trial assessed cabozantinib plus atezolizumab versus sorafenib as first-line systemic treatment for advanced hepatocellular carcinoma.
Subjects
RENAL-CELL CARCINOMA; BEVACIZUMAB; COMBINATION
Publisher
ELSEVIER SCIENCE INC
Type
journal article